Clinical Trial

Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.
Trial Details
NCT Number NCT06405100
Lead Sponsor Air Force Military Medical University, China
Collaborators: First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, The Second Affiliated Hospital of Air Force Military Medical University, Shaanxi Provincial People's Hospital, Shaanxi Provincial Hospital of Chinese Medicine
Conditions Minimal Change Disease
Enrollment 81 participants
Start Date 2024-05
Primary Completion 2026-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2024-05-08